Melissa Mathias

3.1k total citations
37 papers, 778 citations indexed

About

Melissa Mathias is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Melissa Mathias has authored 37 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Immunology and 7 papers in Epidemiology. Recurrent topics in Melissa Mathias's work include CAR-T cell therapy research (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Immunotherapy and Immune Responses (7 papers). Melissa Mathias is often cited by papers focused on CAR-T cell therapy research (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Immunotherapy and Immune Responses (7 papers). Melissa Mathias collaborates with scholars based in United States, Spain and Australia. Melissa Mathias's co-authors include Patrick C. Wilson, Kenneth G. C. Smith, Qingzhao Zhang, Nai‐Ying Zheng, Kristi A. Koelsch, J. Víctor García, Youn Tae Kwak, Daniel A. Powell, Deborah Payne and John F. Krisko and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Melissa Mathias

36 papers receiving 766 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melissa Mathias United States 12 485 211 172 120 103 37 778
Brian H. Santich United States 12 390 0.8× 164 0.8× 109 0.6× 70 0.6× 61 0.6× 19 722
Paul L. Klarenbeek Netherlands 19 561 1.2× 185 0.9× 122 0.7× 62 0.5× 246 2.4× 35 1.0k
Christoph Königs Germany 18 264 0.5× 202 1.0× 89 0.5× 115 1.0× 41 0.4× 78 1.0k
Dimitra Zotos Australia 13 1.2k 2.4× 180 0.9× 50 0.3× 71 0.6× 112 1.1× 16 1.4k
Ellen Kuta United States 8 433 0.9× 152 0.7× 85 0.5× 251 2.1× 155 1.5× 10 693
Aisha Hasan United States 14 257 0.5× 367 1.7× 48 0.3× 77 0.6× 226 2.2× 55 696
C. J. Alcock United Kingdom 9 422 0.9× 122 0.6× 81 0.5× 110 0.9× 91 0.9× 17 774
Laura Beaton Australia 6 1.4k 2.9× 193 0.9× 42 0.2× 83 0.7× 94 0.9× 8 1.6k
Emma Nicholson United Kingdom 12 188 0.4× 173 0.8× 43 0.3× 145 1.2× 46 0.4× 38 527
Francesca Mazzetta Italy 17 480 1.0× 208 1.0× 26 0.2× 145 1.2× 210 2.0× 21 863

Countries citing papers authored by Melissa Mathias

Since Specialization
Citations

This map shows the geographic impact of Melissa Mathias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Mathias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Mathias more than expected).

Fields of papers citing papers by Melissa Mathias

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Mathias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Mathias. The network helps show where Melissa Mathias may publish in the future.

Co-authorship network of co-authors of Melissa Mathias

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Mathias. A scholar is included among the top collaborators of Melissa Mathias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Mathias. Melissa Mathias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rischin, Danny, David Miller, Nikhil I. Khushalani, et al.. (2024). 1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses. Annals of Oncology. 35. S722–S722. 2 indexed citations
2.
Segal, Neil H., Eugenia Girda, Davendra Sohal, et al.. (2024). A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.. Journal of Clinical Oncology. 42(16_suppl). 2503–2503. 5 indexed citations
3.
Segal, Neil H., Eugenia Girda, Lawrence Fong, et al.. (2023). A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.. Journal of Clinical Oncology. 41(4_suppl). TPS277–TPS277. 5 indexed citations
4.
5.
Gross, Neil D., David Miller, Emily S. Ruiz, et al.. (2022). 789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study. Annals of Oncology. 33. S904–S905. 2 indexed citations
6.
7.
Tewari, Krishnansu S., Bradley J. Monk, Ignace Vergote, et al.. (2021). VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. Annals of Oncology. 32(7). 940–941. 20 indexed citations
8.
Mathias, Melissa, Michael V. Ortiz, Kay See Tan, et al.. (2019). Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures. PEDIATRICS. 144(2). 3 indexed citations
9.
He, Aiwu Ruth, Glen J. Weiss, Gerald S. Falchook, et al.. (2018). Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. Annals of Oncology. 29. x26–x26. 8 indexed citations
10.
11.
Chang, Aaron Y., Tao Dao, Ron S. Gejman, et al.. (2017). A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. Journal of Clinical Investigation. 127(7). 2705–2718. 68 indexed citations
12.
Mathias, Melissa, Jonathan T. Sockolosky, Aaron Y. Chang, et al.. (2017). CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia. 31(10). 2254–2257. 11 indexed citations
13.
Mathias, Melissa, Michael V. Ortiz, Heather Magnan, et al.. (2017). A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition. Biomarker Research. 5(1). 7–7. 1 indexed citations
14.
Mathias, Melissa, Alexander J. Chou, Paul A. Meyers, et al.. (2016). Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. Journal of Pediatric Hematology/Oncology. 38(5). e166–e168. 2 indexed citations
15.
Chang, Aaron Y., Ron S. Gejman, Elliott J. Brea, et al.. (2016). Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opinion on Biological Therapy. 16(8). 979–987. 46 indexed citations
16.
Mathias, Melissa & Timothy L. McCavit. (2015). Timing of Opioid Administration as a Quality Indicator for Pain Crises in Sickle Cell Disease. PEDIATRICS. 135(3). 475–482. 18 indexed citations
17.
Denton, Paul W., John F. Krisko, Daniel A. Powell, et al.. (2010). Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice. PLoS ONE. 5(1). e8829–e8829. 135 indexed citations
18.
Duty, J. Andrew, Péter Szodoray, Nai‐Ying Zheng, et al.. (2008). Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. The Journal of Experimental Medicine. 206(1). 139–151. 183 indexed citations
19.
Koelsch, Kristi A., Nai-Ying Zheng, Qingzhao Zhang, et al.. (2007). Mature B cells class switched to IgD are autoreactive in healthy individuals. Journal of Clinical Investigation. 117(6). 1558–1565. 109 indexed citations
20.
Casellas, Rafael, Qingzhao Zhang, Nai‐Ying Zheng, et al.. (2007). Igκ allelic inclusion is a consequence of receptor editing. The Journal of Experimental Medicine. 204(1). 153–160. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian H. Santich Breakdown of academic impact, for papers by Paul L. Klarenbeek Breakdown of academic impact, for papers by Christoph Königs Breakdown of academic impact, for papers by Dimitra Zotos Breakdown of academic impact, for papers by Ellen Kuta Breakdown of academic impact, for papers by Aisha Hasan Breakdown of academic impact, for papers by C. J. Alcock Breakdown of academic impact, for papers by Laura Beaton Breakdown of academic impact, for papers by Emma Nicholson Breakdown of academic impact, for papers by Francesca Mazzetta
Rankless by CCL
2026